Clinical Practice Guidelines
The AHS has established guidelines through the help of our Guidelines Committee. These guidelines help promote AHS as the most comprehensive source in the field of headaches for both professionals and patients.
AHS Guidelines and Position Statements
Clinical practice guidelines are systematically developed statements to assist practitioner and patient decisions about appropriate health care for specific clinical circumstances. AHS provides this service to assist all healthcare professionals in their treatment of patients with migraine and related disorders.
Guidelines Committee
The Guidelines Committee works to establish AHS as the authoritative source of information for patients, physicians, and regulatory agencies by developing guidelines and a classification system.
Meet the CommitteeAHS Guidelines Policies
Publications
Access the current list of AHS Guidelines, Position Statements, Evidence Assessments, and Consensus Opinions published in the journal Headache®.
2024
Andrew C. Charles MD, Kathleen B. Digre MD, Peter J. Goadsby MD, PhD, Matthew S. Robbins MD, Andrew Hershey MD, PhD, The American Headache Society. (2024) Calcitonin gene-related peptide-targeting therapies are a first-line option for the prevention of migraine: An American Headache Society position statement update.
2021
Jessica Ailani MD, Rebecca C. Burch MD, Matthew S. Robbins MD, on behalf of the Board of Directors of the American Headache Society. (2021) The American Headache Society Consensus Statement: Update on integrating new migraine treatments into clinical practice.
2019
Oskoui M, Pringsheim T, Holler-Managan Y, Potrebic S, Billinghurst L, Gloss D, Hershey AD, Licking N, Sowell M, Victorio MC, Gersz EM, Leininger E, Zanitsch H, Yonker M, Mack K. (2019) Practice guideline update summary: Acute treatment of migraine in children and adolescents: Report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology and the American Headache Society.
2018
Digre, K.., American Headache Society
2016
Pringsheim, T., Davenport, W. J., Marmura, M. J., Schwedt, T. J. and Silberstein, S. (2016), How to Apply the AHS Evidence Assessment of the Acute Treatment of Migraine in Adults to your Patient with Migraine. Headache, 56: 1194–1200. doi:10.1111/head.12870
2016
Robbins MS, Starling AJ, Pringsheim TM, Becker WJ, Schwedt TJ. Treatment of Cluster Headache: The American Headache Society Evidence-Based Guidelines. Headache. 2016 Jul;56(7):1093-106. doi: 10.1111/head.12866.
2016
Orr, S. L., Friedman, B. W., Christie, S., Minen, M. T., Bamford, C., Kelley, N. E. and Tepper, D. (2016), Management of Adults With Acute Migraine in the Emergency Department: The American Headache Society Evidence Assessment of Parenteral Pharmacotherapies. Headache: The Journal of Head and Face Pain, 56: 911–940. doi:10.1111/head.12835
2015
Marmura MJ1, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache. 2015 Jan;55(1):3-20. doi: 10.1111/head.12499.
2013
Loder, E., Weizenbaum, E., Frishberg, B., Silberstein, S. and American Headache Society Choosing Wisely Task Force (2013), Choosing Wisely in Headache Medicine: The American Headache Society’s List of Five Things Physicians and Patients Should Question. Headache: The Journal of Head and Face Pain, 53: 1651–1659. doi:10.1111/head.12233
2012
Loder E, Burch R, Rizzoli P. The 2012 AHS/AAN guidelines for prevention of episodic migraine: a summary and comparison with other recent clinical practice guidelines. Headache. 2012 Jun;52(6):930-45. doi: 10.1111/j.1526-4610.2012.02185.x.
2010
Evans, R. W., Tepper, S. J., Shapiro, R. E., Sun-Edelstein, C. and Tietjen, G. E. (2010), The FDA Alert on Serotonin Syndrome With Use of Triptans Combined With Selective Serotonin Reuptake Inhibitors or Selective Serotonin-Norepinephrine Reuptake Inhibitors: American Headache Society Position Paper. Headache: The Journal of Head and Face Pain, 50: 1089–1099. doi:10.1111/j.1526-4610.2010.01691.x
2005
Penzien, D. B., Andrasik, F., Freidenberg, B. M., Houle, T. T., Lake, A. E., Lipchik, G. L., Holroyd, K. A., Lipton, R. B., McCrory, D. C., Nash, J. M., Nicholson, R. A., Powers, S. W., Rains, J. C. and Wittrock, D. A. (2005), Guidelines for Trials of Behavioral Treatments for Recurrent Headache, First Edition: American Headache Society Behavioral Clinical Trials Workgroup. Headache: The Journal of Head and Face Pain, 45: S110–S132. doi:10.1111/j.1526-4610.2005.4502004.x
2004
Dodick, D., Lipton, R. B., Martin, V., Papademetriou, V., Rosamond, W., MaassenVanDenBrink, A., Loutfi, H., Welch, K.Michael., Goadsby, P. J., Hahn, S., Hutchinson, S., Matchar, D., Silberstein, S., Smith, T. R., Purdy, R. A., Saiers, J. and The Triptan Cardiovascular Safety Expert Panel (2004), Consensus Statement: Cardiovascular Safety Profile of Triptans (5-HT1B/1D Agonists) in the Acute Treatment of Migraine. Headache: The Journal of Head and Face Pain, 44: 414–425. doi:10.1111/j.1526-4610.2004.04078.x